Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...